| Demographics |
| Sex, m/f (%) | 8 (38)/13 (62) | 25 (68)/12 (32) | .029 |
| Age (years) | 60 (52–71) | 60 (52–67) | .686 |
| BMI (kg/m2) | 24 (20–30) | 25 (23–29) | .340 |
| ASA, n (%) | | | .460 |
| I | 2 (10) | 1 (3) | |
| II | 5 (24) | 12 (42) | |
| III | 14 (67) | 24 (65) | |
| Rescue ALPPS after failed TSH, n (%) | 6 (29) | n.a. | n.a. |
| Oncologic characteristics |
| Timing: synchronous/metachronous | 9 (43)/12 (57) | 24 (65)/13 (35) | .104 |
| Site of primary | | | .145 |
| Right-sided colon | 6 (29) | 4 (11) | |
| Left-sided colon | 10 (48) | 17 (46) | |
| Rectum | 5 (24) | 16 (43) | |
| T category primary | | | .581 |
| I/II | 3 (14) | 3 (9) | |
| III/IV | 18 (86) | 29 (91) | |
| N category primary | | | .001 |
| N0 | 9 (43) | 2 (6) | |
| N1 | 12 (57) | 30 (94) | |
| Preoperative chemotherapy (y/n) | 20 (95)/1 (5) | 21 (57)/16 (43) | |
| Number of chemotherapy lines, n (%) | | | .038 |
| First-line treatment | 20 (95) | 27 (73) | |
| Second-line treatment | 3 (14) | 7 (19) | |
| Number of cycles of chemotherapy | 8 (6–13) | 6 (0–13) | .243 |
| Chemotherapeutic substance in first line, n (%) | | | .312 |
| Oxaliplatin | 13 (62) | 14 (38) | |
| Irinotecan | 4 (19) | 2 (5) | |
| Oxaliplatin and Irinotecan | 2 (10) | 6 (16) | |
| Other/unknown | 2 (10) | 5 (14) | |
| Chemotherapeutic substance in second line, n (%) | | | .788 |
| Oxaliplatin | 0 | 1 (14) | |
| Irinotecan | 1 (33) | 3 (43) | |
| Oxaliplatin and Irinotecan | 2 (67) | 2 (29) | |
| Other | 0 | 1 (14) | |
| Antibody utilization, n (%) | 14 (67) | 17 (46) | .128 |
| Antibody, n (%) | | | .476 |
| Bevacizumab | 7 (50) | 12 (71) | |
| Cetuximab | 5 (36) | 4 (24) | |
| Panitumumab | 2 (14) | 1 (6) | |
| Response to chemotherapy, n (%)# | | | .794 |
| Stable disease | 9 (45) | 13 (38.2) | |
| Partial remission | 10 (50) | 20 (58.8) | |
| Progressive disease | 1 (5) | 1 (2.9) | |
| Number of lesions at hepatectomy* | 3 (1–9) | 3 (1–8) | .686 |
| Largest tumor diameter at hepatectomy (mm)* | 42 (10–130) | 33 (4–107) | .237 |
| Liver function and clinical chemistry |
| Albumin (g/l) | 41 (34–44) | 41 (39–46) | .279 |
| AST (U/l) | 32 (27–57) | 31 (24–41) | .189 |
| ALT (U/l) | 32 (22–47) | 27 (20–38) | .197 |
| GGT (U/l) | 109 (47–316) | 67 (34–173) | .080 |
| Total bilirubin (mg/dl) | 0.4 (0.2–0.6) | 0.4 (0.3–0.6) | .336 |
| Platelet count (/nl) | 254 (196–295) | 257 (199–295) | .986 |
| Alkaline Phosphatase (U/l) | 148 (91–189) | 92 (76–131) | .029 |
| Prothrombin time (%) | 100 (84–104) | 100 (93–111) | .200 |
| Hemoglobin (g/dl) | 11.9 (9.9–13.1) | 13.2 (12.4–14.5) | .003 |
